Cisplatin-induced growth arrest of head and neck cancer cells correlates with increased expression of p16 and p53

Archives of Otolaryngology - Head and Neck Surgery

Volumn 132, Issue 3, 2006, Pages 317-326

  Yip, Helena T ^a   Chopra, Rajesh ^a   Chakrabarti, Rita ^b   Veena, Mysore S ^b   Ramamurthy, Bharathi ^b   Srivatsan, Eri S ^b   Wang, Marilene B ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PROTEIN BCL XL; PROTEIN C JUN; PROTEIN P16; PROTEIN P21; PROTEIN P53;

AMINO ACID SEQUENCE; ARTICLE; CANCER CELL; CELL CYCLE; CELL SORTER; CHEMICAL ANALYSIS; GROWTH DISORDER; HEAD AND NECK CANCER; IMMUNOFLUORESCENCE; IN VITRO STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CARCINOMA, SQUAMOUS CELL; CASPASE 3; CASPASES; CELL DEATH; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-JUN; PROTO-ONCOGENE PROTEINS C-MDM2; RETINOBLASTOMA PROTEIN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33645226947     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archotol.132.3.317     Document Type: Article

References (47)

1. Brunin F, Mosseri V, Jaulerry C, Point D, Cosset JM, Rodriguez J. Cancer of the base of the tongue: past and future. Head Neck. 1999;21:751-759.
2. Samant S, Kumar P, Wan J, et al. Concomitant radiation therapy and targeted cisplatin chemotherapy for the treatment of advanced pyriform sinus carcinoma: disease control and preservation of organ function. Head Neck. 1999;21:595-601.
3. De Andres L, Brunet J, Lopez-Pousa A, et al. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol. 1995;13:1493-1500.
4. Glicksman AS, Slotman G, Doolittle C, et al. Concurrent cis-platinum and radiation with or without surgery for advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 1994;30:1043-1050.
5. Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593-1598.
6. Joschko MA, Webster LK, Bishop JF, et al. Radioenhancement by cisplatin with accelerated fractionated radiotherapy in a human tumour xenograft. Cancer Chemother Pharmacol. 1997;40:534-539.
7. Muller D, Millon R, Lidereau R, et al. Frequent amplification of 11q13 DNA markers is associated with lymph node involvement in human head and neck squamous cell carcinoma. Eur J Cancer B Oral Oncol. 1994;30B:113-120.
8. Akervall JA, Jin Y, Wennerberg JP, et al. Chromosomal abnormalities involving 11ql3 are associated with poor prognosis in patients with squamous cell carcinoma of the head and neck. Cancer. 1995;76:853-859.
9. Meredith SD, Levine PA, Burns JA, et al. Chromosome 11q13 amplification in head and neck squamous cell carcinoma: association with poor prognosis. Arch Otolaryngol Head Neck Surg. 1995;121:790-794.
10. Michalides RJ, van Veelen NM, Kristel PM, et al. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1997;123:497-502.
11. Takes RP, Battenburg de Jong RJ, Schuuring E, et al. Markers of assessment of nodal metastasis in laryngeal carcinoma. Arch Otolaryngol Head Neck Surg. 1997;123:412-419.
12. Namazie A, Alavi S, Olopade O, et al. Cyclin D1 amplification and p16 (MTS1/ CDK4I) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope. 2002;112:472-481.
13. Yoo GH, Xu HJ, Brennan JA, et al. Infrequent inactivation of the retinoblastoma gene despite frequent loss of chromosome 13q in head and neck squamous cell carcinoma. Cancer Res. 1994;54:4603-4606.
14. Wang MB, Yip HT, Srivatsan ES. Antisense cyclin D1 enhances sensitivity of head and neck cancer cells to cisplatin. Laryngoscope. 2001;111:982-988.
15. Nakashima T, Clayman GL. Antisense inhibition of cyclin D1 in human head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2000;126:957-961.
16. Trimmer EE, Essigman JM. Cisplatin. Essays Biochem. 1999;34:191-211.
17. Lee RJ, Albanese C, Fu M, et al. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol. 2000;20:672-683.
18. Wang SJ, Mintz LE, Natarajan V, Lee NJ, Srivatsan ES, Wang MB. Antisense cyclin D1 inhibits growth of head and neck cancer xenografts in nude mice Otolaryngol Head Neck Surg. 2001;124:656-662.
19. Paquette RL, Lee YY, Wilczynski SP, et al. Mutations of p53 and human papillomavirus infection in cervical carcinoma. Cancer. 1993;72:1272-1280.
20. Kim MS, Li SL, Bertolami CN, Cherrick HM, Park NH. State of p53, Rb and DCC tumor suppressor genes in human oral cancer cell lines. Anticancer Res. 1993;13(5A):1405-1413.
21. Minn AJ, Boise LH, Thompson CB. Bcl-x(S) antagonizes the protective effects of Bcl-x(L). J Biol Chem. 1996;271:6306-6312.
22. Kornmann M, Arber N, Korc M. Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest. 1998;101:344-352.
23. Kornmann M, Danenberg K, Arber N, Beger H, Danenberg P, Korc M. Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res. 1999;59:3505-3511.
24. Timmer-Bosscha H, Mulder HN, de Vries EGE. Modulation of cis-diamminedichloroplatinum (II) resistance: a review. Br J Cancer. 1992;66:227-238.
25. Chao CC. Molecular basis of cis-diamminedichloroplatinum (II) resistance: a review. J Formos Med Assoc. 1996;95:893-900.
26. Perez RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer. 1998;34:1535-1542.
27. Dempke W, Voigt W, Grothey A, Hill BT, Schmoll H-J. Cisplatin resistance and oncogenes - a review. Anticancer Drugs. 2000;11:225-236.
28. Shellard SA, Hosking LK, Hill BT. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian cell lines in vitro. Cancer Res. 1991;51:4557-4564.
29. Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and crossresistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res. 1997;57:850-856.
30. Warenius HM, Seabra LA, Maw P. Sensitivity to cis- diamminedichloroplatinum in human cancer cells is related to expression of cyclin D1 but not to c-raf-1 protein. Int J Cancer. 1996;67:224-231.
31. Sorenson CM, Barry MA, Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst. 1990;82:749-755.
32. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells. 1990;2:275-280.
33. Gallagher WM, Cairney M, Schott B, Roninson IB, Brown R. Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene. 1997;14:185-193.
34. Kern MA, Helmbach H, Artuc M, Karmann D, Jurgovsky K, Schadendorf D. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustin, vindesin or etoposide: modulation of proto-oncogene expression. Anticancer Res. 1997;17:4359-4370.
35. Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood. 1994;84:3148-3157.
36. Eliopoulos AG, Kerr DJ, Herod J, et al. The control of apoptosis and drug resistance in ovarian cancer. Oncogene. 1995;11:1217-1228.
37. Lenz HJ, Hayashi K, Salonga D, et al. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res. 1998;4:1243-1250.
38. Kigawa J, Sato S, Shimada M, et al. p53 gene status and chemosensitivity in ovarian cancer. Hum Cell. 2001;14:165-171.
39. Bradford CR, Zhu S, Ogawa H, et al. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck. 2003;25:654-661.
40. Takaoka A, Hayakawa S, Yanai H, et al. Integration of interferon-α/β signaling to p53 responses in tumour suppression and antiviral defence. Nature. 2003;424:516-523.
41. Wang X, Wong SC, Pan J, et al. Evidence of cisplatin-induced senescent-like growth arrest in nasopharyngeal carcinoma cells. Cancer Res. 1998;58:5019-5022.
42. Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P. p53 mutations in nonastrocytic human brain tumors. Cancer Res. 1991;51:6202-6205.
43. Pavelic ZP, Li YQ, Stambrook PJ, et al. Overexpression of p53 protein is common in premalignant head and neck lesions. Anticancer Res. 1994;14:2259-2266.
44. Grote HJ, Schneider-Stock R, Neumann W, Roessner A. Mutation of p53 with loss of heterozygosity in the osteosarcomatous component of a dedifferentiated chondrosarcoma. Virchows Arch. 2000;436:494-497.
45. Chen CR, Wang W, Rogoff HA, Li X, Mang W, Li CJ. Dual induction of apoptosis and senescence in cancer cells by Chk2 activation: checkpoint activation as a strategy against cancer. Cancer Res. 2005;65:6017-6021.
46. Lindenboim L, Borner C, Stein R. Bcl-x(S) can form homodimers and heterodimers and its apoptotic activity requires localization of Bcl-x(S) to the mitochondria and its BH3 and loop domains. Cell Death Differ. 2001;8:933-942.
47. Bauer JA, Trask DK, Kumar B, et al. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. Mol Cancer Ther. 2005;4:1096-1104.